相似文献
1
Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody.
Gut. 2004 Jul;53(7):1032-4. doi: 10.1136/gut.2003.036806.
2
Celiac disease associated with nodular regenerative hyperplasia, pulmonary abnormalities, and IgA anticardiolipin antibodies.
J Clin Gastroenterol. 2006 Feb;40(2):135-9. doi: 10.1097/01.mcg.0000196462.53304.bf.
3
Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant.
Scand J Rheumatol. 1997;26(3):215-7. doi: 10.3109/03009749709065684.
4
Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease.
Z Gastroenterol. 2006 May;44(5):395-8. doi: 10.1055/s-2006-926581.
5
Clinical analysis of 15 cases of liver nodular regenerative hyperplasia.
Cell Biochem Biophys. 2012 Nov;64(2):115-21. doi: 10.1007/s12013-012-9379-5.
6
[Clinicopathological observaton on nodular regenerative hyperplasia of the liver].
Zhonghua Bing Li Xue Za Zhi. 2002 Feb;31(1):34-7.
7
Nodular regenerative hyperplasia of the liver: clinical and radiologic observations.
AJR Am J Roentgenol. 1987 Apr;148(4):717-22. doi: 10.2214/ajr.148.4.717.
8
Hepatic infarction and nodular regenerative hyperplasia of the liver with associated anticardiolipin antibodies in a young woman.
J Clin Gastroenterol. 1994 Jun;18(4):309-13. doi: 10.1097/00004836-199406000-00010.
9
Outcomes of idiopathic versus secondary nodular regenerative hyperplasia of the liver: A longitudinal study of 167 cases.
Liver Int. 2022 Jun;42(6):1379-1385. doi: 10.1111/liv.15202. Epub 2022 Feb 28.
10
Nodular regenerative hyperplasia of the liver in a patient with celiac disease.
J Clin Gastroenterol. 2001 Oct;33(4):323-6. doi: 10.1097/00004836-200110000-00014.
引用本文的文献
1
Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management.
Hepatol Int. 2024 Dec;18(6):1684-1711. doi: 10.1007/s12072-024-10739-6. Epub 2024 Nov 15.
2
A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma.
Surg Case Rep. 2024 Feb 1;10(1):30. doi: 10.1186/s40792-024-01820-1.
3
A Narrative Review on Non-Cirrohotic Portal Hypertension: Not All Portal Hypertensions Mean Cirrhosis.
Diagnostics (Basel). 2023 Oct 20;13(20):3263. doi: 10.3390/diagnostics13203263.
4
Management of liver disease and portal hypertension in common variable immunodeficiency (CVID).
JHEP Rep. 2023 Aug 13;5(11):100882. doi: 10.1016/j.jhepr.2023.100882. eCollection 2023 Nov.
5
Liver disease accompanied by enteropathy in common variable immunodeficiency: Common pathophysiological mechanisms.
Front Immunol. 2022 Oct 20;13:933463. doi: 10.3389/fimmu.2022.933463. eCollection 2022.
6
Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.
Gastroenterology Res. 2021 Apr;14(2):49-65. doi: 10.14740/gr1376. Epub 2021 Apr 21.
7
Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis.
Front Med (Lausanne). 2021 Feb 4;8:630660. doi: 10.3389/fmed.2021.630660. eCollection 2021.
8
What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors.
Indian J Med Res. 2019 Apr;149(4):468-478. doi: 10.4103/ijmr.IJMR_1405_17.
9
Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report.
World J Hepatol. 2019 May 27;11(5):483-488. doi: 10.4254/wjh.v11.i5.483.
10
Idiopathic noncirrhotic portal hypertension: current perspectives.
Hepat Med. 2016 Jul 27;8:81-8. doi: 10.2147/HMER.S85544. eCollection 2016.
本文引用的文献
1
Coeliac disease: dissecting a complex inflammatory disorder.
Nat Rev Immunol. 2002 Sep;2(9):647-55. doi: 10.1038/nri885.
2
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.
Gut. 2002 Aug;51(2):275-80. doi: 10.1136/gut.51.2.275.
3
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.
Arthritis Rheum. 1999 Jul;42(7):1309-11. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.
4
Determinant spreading: lessons from animal models and human disease.
Immunol Rev. 1998 Aug;164:209-29. doi: 10.1111/j.1600-065x.1998.tb01222.x.
5
Systemic exposure to irradiated apoptotic cells induces autoantibody production.
J Exp Med. 1998 Jul 20;188(2):387-92. doi: 10.1084/jem.188.2.387.
6
Increased prevalence of autoantibodies in celiac disease.
Dig Dis Sci. 1998 Apr;43(4):723-6. doi: 10.1023/a:1018801711413.
7
Increased small intestinal apoptosis in coeliac disease.
Gut. 1996 Dec;39(6):811-7. doi: 10.1136/gut.39.6.811.
8
Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome.
Thromb Haemost. 1995 Nov;74(5):1361-7.
9
10
Nodular transformation (nodular "regenerative" hyperplasia) of the liver. A clinicopathologic study of 30 cases.
Hum Pathol. 1981 Jan;12(1):60-71. doi: 10.1016/s0046-8177(81)80242-0.
Zotero 插件